Archives: Speakers

Session Details: KEYNOTE REUNION DEBATE, 1 YEAR ON: Post-COVID-19 in the new world Debating how COVID-19 will impact the way we outsource and conduct clinical trials in the future; a follow up from our 2021 session, what has changed? 29-11-2022, 4:30 pm PANEL DISCUSSION: Clinical trials in Asia (Korea, China, Taiwan, India, Singapore) ‘Unlocking efficient strategies to manage multiple countries’ regulations for global trials to increase productivity and achieve high quality results from all operation sites

Jae-Hyun (Jay) Park is a new drug developer, Ph.D., and a Korean pharmacist. He has experience in research institutes and strategic planning teams of large Korean pharmaceutical companies and start-ups. Jay has expertise in various fields such as non-clinical research, patents, and technology licensing. Currently, he is developing a new drug to treat COVID19 using natural substances.

Jeesun Lee is Clinical Development Director at Shaperon, currently working on a multinational Phase 2b/3 clinical trial of COVID-19 pneumonia. Prior to working at Shaperon, Jeesun has 8 years of experience as a pharmaceutical physician, Medical Manager and Oncology Business Unit Medical Lead from Pfizer Korea, where she worked across diverse Pfizer portfolio and medical affairs’ activities. Jeesun did her Ph.D. in the Department of Clinical Research Design and Evaluation at Sungkyunkwan University, further developing her professional skills within academia and the working field. She is MD from Korea University, South Korea.

Rainbow has 16 years’ experience in clinical research and drug development in both pharmaceutical and CRO settings. She has thorough understanding of overall product development process from pre-IND through post-marketing, including knowledge of core cross-functional concepts on preclinical, translational medicine, CMC and major requirements at different development stages. She has in-depth knowledge of regulatory requirements and process in Asia Pac especially Greater China and Japan. She has proven capabilities and records in contributing to the business growth and partnership opportunities with emerging biotech in Asia Pac. Furthermore, she has extensive experience in managing pre-clinical through late phase global clinical studies across continents including North American, European and Asia Pac regions. Her therapeutic areas’ experience including Oncology and Hematology, CNS disorder, Respiratory, Cardiovascular, Vaccines, Infectious diseases, Fertility, Internal Medicine and Biosimilars on biologics and chemicals. In addition to her product lifecycle management, clinical project management and customer management expertise, she demonstrates diverse capabilities in various aspects into future state. She possesses strategic vision for her department growth and sustainability, has proven line management skills and is keen in people career development with excellent 360 scores. She also possesses business acumen, customer centricity and result-driven capabilities from business and delivery perspectives. She is strong in innovation, strategies and continuous process improvements such as leading machine translation solutions, risk based monitoring pilot, precision patient recruitment strategies in Merck and leading cross functional initiatives in resourcing optimization and hiring recommendation, customer portfolio lead community as well as bid defense coach program in her years in CRO.

Ms. Juhee Jeon graduated from Korea University with a Master’s of Science in Medical Microbiology (Immunology). She has been working in the field of marketing, medical information, clinical trial drug safety, pharmacovigilance and post-marketing surveillance at pharmaceutical companies and CROs for more than 13 years. In a CRO, Juhee managed the safety monitoring of a global oncology clinical trial. Currently, she is responsible for managing drug safety monitoring in clinical trials and pharmacovigilance covering RWE/RWD at Yungjin Pharm in Korea.

Naima Boutroy is Global Packaging Expert. Within her responsibilities, a specific focus is on sensitive product solutions support, such as packaging and preform performance evaluation, barrier packaging solutions, and recycling.

A Global, Award-Winning Entrepreneur and CEO with more than two decades of experience in the medical cannabis, biotechnology, pharmaceutical, nutraceutical, and medical device industries, Christina’s dedication to revolutionizing patient care is unprecedented. Through her roles as CEO, Spectral Analytics Precision Tele-Monitoring, Founder and CEO of Affinity Bio Partners, Board President and CEO of Affinity Patient Advocacy, Christina has been involved with revolutionary projects and global clinical studies that positively impact patients including formulating new products. Christina has spoken at many events including delivering Keynote addresses as well as organizing her own education events for her multiple companies.

Christina has a personal brand, I am Christina DiArcangelo with a podcast channel (I am Christina DiArcangelo) where she speaks to many exciting, thought-provoking guests. Christina has also developed merchandise under Affinity Patient Advocacy and Christina DiArcangelo and launched a merchandise company called Sparkle Sisters.

Christina has launched an e-magazine called The DiArc. The DiArc is a lifestyle magazine that shines a spotlight on all topics that apply to Christina DiArcangelo.

As an award winning global clinical research pioneer, and Christina is also an Opinion Columnist for CEO WorldBiz, she has utilized the tools at her disposal to champion patient care and provide best-in-class patient advocacy services. For Christina, patient care and safety come first.

As an active Bahai’ and mother to her one son, Christian, she believes that listening, learning, and growing are everyday values that can change the world by impacting our own hearts, homes, and communities.